Abstract
Tuberculosis (TB) is a global health crisis, with millions of cases and deaths annually. Drug-resistant strains like multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB further complicate treatment. Conventional TB treatment, reliant on lengthy drug regimens, faces issues of non-compliance, drug resistance, and side effects. Nanoparticles (NPs) offer a promising solution. NPs, with their small size and unique properties, can enhance TB drug delivery. They improve drug solubility and stability, minimize side effects, and enable targeted therapy. NPs encapsulate drugs, shielding them from degradation during delivery and ensuring controlled drug release at the infection site. NPs' controlled release leads to prolonged drug efficacy, reducing dosing frequency and improving patient compliance. Moreover, NPs can encapsulate multiple drugs, a critical advantage in combating drug-resistant TB strains. In conclusion, NPs hold immense promise in TB treatment. They address the limitations of traditional therapies by improving drug delivery, bioavailability, and targeting drug-resistant TB. Ongoing research in nanoparticles-based formulations offers hope for more effective and patient-friendly TB treatments.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
